Trial to Evaluate Reduction in Inflammation in Patients With Advanced Chronic Renal Disease Utilizing Antibody Mediated IL-6 Inhibition

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 264 participants.

Also called NCT03926117

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 264 participants (enrolled count) (from the registry)
Sponsor
  • Novo Nordisk Registry lists this organization as the lead sponsor
Registry
  • NCT NCT03926117
Other papers using this trial's data
  • IL-6 inhibition with ziltivekimab in patients at high atherosclerotic risk (RESCUE): a double-blind, randomised, placebo-controlled, phase 2 trial Lancet (London, England), 2021-05-29 DOI, PubMed 34015342

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT03926117. Randomized; quadruple masking; primary purpose treatment. Start 2019-06-03 (actual); primary completion 2020-06-26 (actual). Results posted on 2023-08-09.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Trial to Evaluate Reduction in Inflammation in Patients With Advanced Chronic Renal Disease Utilizing Antibody Mediated IL-6 Inhibition
Acronym
RESCUE
Condition
Chronic Kidney Diseases
Condition
Inflammation
Intervention (Biological)
Ziltivekimab
Lead sponsor
Novo Nordisk A/S (class: industry)

Record details

Record id
cardio:ct-nct03926117
Content hash
56ced556ed4d5164c768a9e87d9eb2f525079dd6eafec8e1da09c21df9b16268